Our Science
AAX Biotech has developed two innovative and unique technologies that can be utilized to develop novel antibody therapeutics and to significantly improve antibody-based therapies, including bispecific antibodies and CAR-T cells.
Our Technologies
One of the major challenges in the field of biotherapeutics is the inefficient development pipeline, which hampers timely advancement and deployment. Another critical issue is poor therapeutic performance, which can limit the efficacy and applicability of these treatments.
To address these problems, we have devised two unique solutions that aim to revolutionize the current landscape.
Seqitope™
A high-resolution, high-throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics.
Opti-mAb™
A new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.